Tumor Genomic Testing: Cancer Mutations, Targeted Therapy, and Results

Tumor genomic testing creates a molecular profile of cancer by examining genes, DNA changes, RNA alterations, and sometimes genome-wide biomarkers that may influence diagnosis or treatment. It is broader than checking one mutation and more focused than assuming every DNA change is clinically useful. The central goal is to identify cancer dependencies—alterations that help a tumor grow and that a drug may be able to block. A profile can support an approved targeted therapy, indicate resistance, refine the tumor type, suggest immunotherapy, or help locate a clinical trial. It can also return no actionable finding, uncertain variants, or targets backed only by weak evidence. The report must therefore be interpreted in the context of the cancer’s origin, stage, pathology, prior treatments, specimen quality, and current guidelines. Genomic matching can improve care for selected patients, but a molecular target is not a promise that a drug will work.

• Tumor genomic testing profiles cancer-specific alterations and molecular biomarkers.
• Broad panels can detect mutations, amplifications, deletions, fusions, and genomic signatures.
• Treatment relevance depends on the exact alteration, tumor type, evidence level, and drug approval.
• Tumor-agnostic therapies work across selected cancer types only when evidence supports the biomarker.
• A negative profile may reflect biology, limited coverage, low tumor DNA, or an outdated specimen.
• Complex results may benefit from review by a molecular tumor board.

Table of Contents

• From a Tumor Sample to a Genomic Profile
• What Comprehensive Profiling Measures
• How a Mutation Is Matched to Targeted Therapy
• What Different Result Patterns Mean
• Why a Promising Match May Not Work
• When Repeat Testing Can Help
• Turning a Report Into a Treatment Decision

From a Tumor Sample to a Genomic Profile

Tumor genomic testing begins with a clinical decision, not with sequencing. The oncology team first asks what information could change care: Is a biomarker required for first-line treatment? Is the cancer advanced or recurrent? Has it stopped responding to a targeted drug? Is the diagnosis uncertain? Are clinical trials being considered?

For a solid tumor, the laboratory usually receives tissue from a biopsy or surgery. A pathologist confirms that the sample contains cancer, estimates the proportion of tumor cells, and selects the most suitable area. The laboratory extracts DNA and, when needed, RNA. For blood cancers, blood or bone marrow may directly contain malignant cells. A plasma “liquid biopsy” can analyze circulating tumor DNA when tissue is unavailable or when rapid, repeated sampling is useful.

The assay may be a small panel designed around one cancer type, a broad next-generation sequencing panel covering hundreds of cancer genes, whole-exome sequencing, whole-genome sequencing, RNA sequencing, or a combined platform. Broader is not automatically better. A focused panel may have deeper coverage and faster turnaround for established biomarkers, while a larger profile may identify rare fusions, unusual targets, or trial options.

After sequencing, software aligns the reads to a reference genome, identifies differences, estimates copy number, calls structural changes, and filters technical noise. The laboratory then annotates each alteration using scientific literature, curated databases, regulatory approvals, clinical guidelines, and evidence from trials. Pathologists and molecular scientists determine which findings should be reported and how strongly they are supported.

The report is a clinical interpretation of data, not a complete inventory of every tumor change. Benign alterations are often omitted. Some uncertain variants may be listed, while others fall below reporting thresholds. The test’s gene list, covered regions, detection limits, and specimen quality define what “negative” means.

A matched normal sample—often blood—may be sequenced alongside tumor tissue. This comparison helps distinguish acquired tumor changes from possible inherited variants. Tumor-only assays can still be useful, but they may not reliably establish whether a variant is somatic or germline.

Turnaround can range from several days to several weeks. Timing matters when treatment must begin quickly. In some cancers, a rapid targeted assay is ordered first for urgent biomarkers, followed by broader profiling if tissue and time permit.

What Comprehensive Profiling Measures

A genomic profile may contain several classes of information that answer different questions.

Point mutations and small insertions or deletions can activate an oncogene or disable a tumor-suppressor gene. The exact variant matters. Two changes in the same gene may have opposite effects, and a drug effective against one mutation may not work against another.

Copy-number alterations occur when a tumor gains or loses stretches of DNA. High-level amplification can produce excess copies of a growth-promoting gene. Deletion may remove a tumor suppressor. Copy-number interpretation depends on tumor purity, ploidy, assay thresholds, and whether protein overexpression is also demonstrated.

Gene rearrangements and fusions can join parts of two genes or move regulatory elements. Some create abnormal kinases that are strong therapeutic targets. RNA analysis can be especially valuable because it shows the expressed fusion transcript, although poor RNA quality can limit detection.

Microsatellite instability and mismatch-repair status reflect failure of a DNA-repair system. MSI-high or mismatch-repair-deficient tumors may respond to immune checkpoint inhibition in appropriate clinical settings. These findings can also signal a possible inherited syndrome, so hereditary evaluation may be indicated.

Tumor mutational burden estimates how many qualifying mutations occur per megabase of assessed DNA. High TMB can support immunotherapy in defined settings, but the score varies by platform, tumor type, filtering, and cutoff. It is not a universal measure of response.

Homologous recombination deficiency attempts to identify impaired repair of double-strand DNA breaks. Tests may analyze selected genes, genomic scarring, loss of heterozygosity, or composite scores. A positive result can be relevant to platinum agents or PARP inhibitors in specific cancers, but utility is not identical across diseases.

Gene expression, methylation, and other molecular classifiers can refine diagnosis or identify a tumor subtype. In some brain tumors and sarcomas, molecular classification can be as important as the microscopic appearance. These classifiers depend on the quality and diversity of the reference dataset.

Mutational signatures describe patterns left by particular biological processes, such as ultraviolet exposure, tobacco carcinogens, defective DNA repair, or prior treatment. Some are clinically useful; others remain primarily research tools.

The profile may also list variant allele fraction, which is the percentage of sequencing reads containing an alteration. It can provide clues about clonality but is affected by tumor-cell percentage, copy-number changes, normal-cell contamination, and assay bias. It should not be interpreted as a direct measure of how much cancer is present or as proof that a variant is inherited.

Comprehensive profiling is a form of somatic genetic testing, but its value lies in integrating multiple alteration types rather than simply producing a longer mutation list.

How a Mutation Is Matched to Targeted Therapy

Targeted therapy aims at a molecular feature that contributes to cancer growth or survival. Matching begins by deciding whether the alteration is a true driver and whether inhibiting it has demonstrated clinical benefit.

The strongest evidence usually involves a therapy approved for the exact biomarker in the patient’s cancer type and disease setting. A validated companion diagnostic may be required. Examples include kinase inhibitors for selected activating mutations or fusions, antibodies for amplified or overexpressed receptors, and drugs that exploit defective DNA-repair pathways.

Evidence becomes less certain as the match moves farther from this setting. A drug might be approved for the same gene alteration in another cancer, supported by a small basket trial, described only in case reports, or active only in laboratory models. The biological target may be shared, but tissue context changes signaling, drug delivery, immune environment, and resistance.

Actionability frameworks help organize this evidence. The ESMO Scale for Clinical Actionability of molecular Targets ranks alterations according to the strength of clinical evidence and whether access should be routine, investigational, or not recommended. Other systems use tiers, levels, or categories. The labels differ, so the report’s definitions must be read rather than assumed.

A tumor-agnostic or tissue-agnostic therapy is approved based primarily on a biomarker rather than the organ where the cancer started. This approach has been used for selected fusions, mismatch-repair deficiency, MSI-high status, high TMB, and other rare molecular subsets. “Agnostic” does not mean biology is irrelevant. Approvals have precise eligibility criteria, required assays, prior-treatment conditions, age limits, and evidence boundaries.

Clinical trials expand the range of possible matches. Basket trials test one targeted strategy across multiple tumor types sharing a biomarker. Umbrella trials assign different treatments within one cancer type based on molecular findings. Platform trials can add or retire treatment arms as evidence changes.

The report may list therapies and trials automatically, but the oncologist must verify:

• The exact variant, not merely the gene name
• Whether the alteration activates or disables the target
• The cancer type and line of therapy studied
• Regulatory status and guideline support
• Required companion diagnostic
• Co-occurring resistance alterations
• Trial location, eligibility, and current enrollment

A molecular match is therefore a hypothesis supported by a particular level of evidence. It becomes a treatment decision only after clinical review.

What Different Result Patterns Mean

Tumor genomic reports often fall into recognizable patterns, each with different implications.

A high-evidence actionable alteration is found. The result may support a standard targeted therapy, immunotherapy, or approved combination. The next step is to confirm that the patient meets all clinical and regulatory criteria. An actionable finding can be important even when it is rare.

Several potentially actionable alterations are found. More options do not necessarily mean more benefit. The alterations may belong to the same pathway, represent different subclones, or include a resistance mechanism. Priority usually goes to the best-validated target for that cancer and treatment setting. Combination therapy can increase toxicity and should not be improvised outside evidence-based care or a clinical trial.

A driver is found, but no approved treatment applies. The alteration may clarify diagnosis or prognosis and support trial enrollment. It should not be described as useless; it simply lacks a current standard therapeutic match.

Only variants of uncertain significance are reported. A VUS has insufficient evidence for treatment selection. Finding it in an oncogene does not make it actionable. Databases and publications may later clarify its role, but speculative matching can expose a patient to ineffective therapy.

No actionable alteration is detected. This can mean the tumor lacks a known target, the relevant biology is not genomic, the assay did not cover the alteration, or the sample contained too little tumor DNA. Standard treatments may still be highly effective. “No actionable mutation” is not the same as “no treatment options.”

A possible inherited variant appears. Tumor profiling can find a change compatible with a hereditary cancer syndrome. Confirmation requires a separate non-tumor sample and appropriate genetic test interpretation. A confirmed germline result can affect therapy, future cancer surveillance, and relatives.

The assay fails or is indeterminate. Insufficient tissue, degraded DNA or RNA, low tumor content, or technical artifacts may prevent a valid result. This is not a negative profile. Another block, a new biopsy, a focused assay, or plasma testing may be considered.

A resistance alteration appears. The result may explain progression and point toward a next-generation inhibitor, a different pathway, or a trial. Some resistance mechanisms are targetable; others indicate that continuing the same drug is unlikely to help.

The report date is part of interpretation. A finding with no option today may become actionable later, while a treatment association may weaken after new trials. Reassessment is particularly relevant at progression.

Why a Promising Match May Not Work

Precision oncology can create a compelling story: identify the mutation, give the matching drug, and stop the tumor. Real cancers are more complex.

First, a detected alteration may not be the dominant driver. It can be a passenger, a weak contributor, or confined to a small subclone. Blocking it may leave the main growth pathway untouched.

Second, tumors contain multiple signaling routes. A co-occurring mutation can activate a downstream or parallel pathway, bypassing the target. Loss of a tumor suppressor may change sensitivity even when the nominal target is present.

Third, tissue context matters. The same alteration can behave differently in lung, colon, thyroid, brain, or pancreatic cancer because the surrounding regulatory network differs. A drug successful in one tumor type may fail in another despite an identical gene label.

Fourth, drug exposure may be inadequate. The medicine may not penetrate the brain or another protected site, the patient may not tolerate an effective dose, or interactions may alter concentration. A molecular target cannot overcome pharmacologic limitations.

Fifth, the tumor evolves under treatment. Pre-existing resistant cells can expand, the target can mutate, the tumor can amplify another gene, or the cancer can change phenotype. Initial response does not guarantee durability.

Sixth, the biomarker assay may not be equivalent to the test used in the supporting study. TMB, HRD, amplification, and expression thresholds differ across platforms. A result just above a cutoff may not carry the same evidence as a strongly positive result from a validated companion diagnostic.

Seventh, the evidence may be preliminary. Case reports and early-phase trials are valuable for generating hypotheses, but response rates can be modest and patient selection can influence results. Trial-listed does not mean effective, and “potential benefit” should not be presented as certainty.

Finally, the patient’s overall condition matters. Organ function, symptoms, prior toxicities, other illnesses, performance status, treatment goals, and availability may make a theoretically matched therapy unsuitable.

These limits do not make genomic testing futile. They explain why actionability must be graded and why standard therapies, pathology, imaging, and clinical judgment remain essential. Testing is most useful when it rules in an evidence-supported option or guides a well-designed trial—not when it turns every variant into a drug suggestion.

When Repeat Testing Can Help

A tumor’s genome can change, so an old profile may become incomplete. Repeat testing is most valuable when there is a clear new question.

After progression on targeted therapy, sequencing may reveal an acquired resistance mutation. This can support a next-generation inhibitor or show that the original target is no longer the best strategy. In some cancers, plasma testing can identify resistance rapidly and capture DNA from several metastatic sites.

Repeat profiling may also help when the first specimen was small, poorly preserved, or obtained before major treatment. A newer metastatic biopsy can better represent current disease. A test performed years ago may have covered far fewer genes and biomarkers than current standards.

Another reason is a new therapy or trial that requires a biomarker not previously measured. The original raw data might support reanalysis, but some biomarkers need a different assay, fresh tissue, RNA, or a validated companion diagnostic.

Serial circulating tumor DNA can sometimes track molecular response or minimal residual disease. A falling signal may correlate with treatment response, while a rising signal can precede radiographic progression. However, the clinical meaning and recommended action vary by cancer. Changing treatment solely because of a molecular rise is not standard in every setting.

Repeat testing has limits. More sequencing can produce more uncertain findings without improving care. A new biopsy carries cost and procedural risk. Plasma tests can be falsely negative when a tumor sheds little DNA, and clonal hematopoiesis can create misleading variants from blood cells.

Before repeating, ask:

1. What changed clinically?
2. What decision could the new result alter?
3. Is tissue or plasma more likely to answer the question?
4. Was the earlier assay technically adequate?
5. Are there new validated biomarkers or trials?
6. Would the patient be eligible for the resulting treatment?

Reinterpretation of the existing report may sometimes be enough. A molecular tumor board or updated knowledge base can identify newly approved options without another specimen, provided the original assay covered the relevant alteration accurately.

Turning a Report Into a Treatment Decision

The full report should be reviewed with the oncologist, not only through a portal summary. Start with the specimen: where and when was it collected, how much tumor was present, and was it taken before or after key therapies? Then review the assay scope and whether DNA, RNA, fusions, copy number, MSI, TMB, or other relevant biomarkers were included.

For each reported target, determine the evidence level and clinical context. A useful discussion separates options into:

• Standard, guideline-supported treatment for this cancer
• Regulatory-approved tumor-agnostic treatment with matching eligibility
• Off-label treatment supported by meaningful clinical evidence
• Biomarker-selected clinical trial
• Research hypothesis without sufficient evidence for care

Ask whether a companion diagnostic is required and whether the performed test qualifies. Some broad panels can identify an alteration but may not be the approved assay for a specific drug. Confirmatory testing may be needed.

Complex reports can be reviewed by a molecular tumor board. These multidisciplinary groups may include medical oncologists, pathologists, geneticists, pharmacists, bioinformaticians, trial specialists, and disease experts. They can resolve nomenclature, assess co-mutations, rank evidence, and locate realistic trials. Their recommendation still needs to fit the patient’s preferences and medical condition.

Possible hereditary implications should not be overlooked. A tumor finding in a cancer-predisposition gene, young age, multiple primary cancers, or a suggestive family history may justify germline testing even if the tumor report calls the alteration somatic. A confirmed inherited result has implications beyond the current tumor.

When no target is found, the conversation should return to all available treatment options rather than framing the test as a failure. Chemotherapy, endocrine therapy, immunotherapy, radiation, surgery, supportive care, and non-biomarker trials remain important. In many cancers, established clinicopathologic factors guide treatment more reliably than a broad profile.

Preserve the report and pathology information. Future interpretation requires exact variant notation, assay version, coverage, and specimen date. Because evidence changes quickly, ask when reassessment would be appropriate—especially at recurrence or progression.

The best use of tumor genomic testing is disciplined rather than maximalist: test at a time when results can matter, use a method capable of detecting the relevant biomarkers, rank findings by evidence, and match the molecular information to the person—not merely to a drug database.

References

1. National Cancer Institute: Biomarker Testing for Cancer Treatment
2. ESMO Recommendations for the Use of Next-Generation Sequencing in Advanced Cancer in 2024
3. ESMO Scale for Clinical Actionability of Molecular Targets
4. National Cancer Institute: Agnostic Cancer Therapies
5. National Cancer Institute: What Comes After NCI-MATCH?
6. National Cancer Institute: Cancer Genome Research and Precision Medicine

Disclaimer

This article is educational and does not replace personalized oncology care, pathology review, or interpretation by a qualified molecular genetics professional. A reported target does not guarantee that a treatment is approved, safe, available, or effective for a particular cancer. Treatment decisions should incorporate current guidelines, evidence level, specimen quality, prior therapy, overall health, and the patient’s goals.